The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Cited by (308)

Items 101–200 of 308

1. Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell‐intrinsic properties
   Peter W. Eide, Ina Andrassy Eilertsen, Anita Sveen, Ragnhild A. Lothe · 2018 · International Journal of Cancer
2. The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway
   Margherita Pergolizzi, Laura Bizzozero, Federica Maione, Elena Maldi, Claudio Isella, Marco Macagno, Elisa Mariella, Alberto Bardelli, Enzo Médico, Caterina Marchiò et al. · 2022 · Journal of Experimental & Clinical Cancer Research
3. Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology
   Catherine Vander Linden, Cyril Corbet · 2019 · Seminars in Cell and Developmental Biology
4. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
   Knickelbein, Kyle, Tong, Jingshan, Chen, Dongshi, Wang, Yi-Jun, Misale, Sandra, Bardelli, Alberto, Yu, Jian, Zhang, Lin · 2018 · Oncogene
5. Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
   Katherine Eason, Anguraj Sadanandam · 2016 · Cancer Research
6. Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis
   Siyuan Ma, Shuji Ogino, Princy Parsana, Reiko Nishihara, Zhirong Qian, Jeanne Shen, Kosuke Mima, Yohei Masugi, Yin Cao, Jonathan Andrew Nowak et al. · 2018 · Genome biology
7. Short tandem repeat profiling for the authentication of cancer stem‐like cells
   Paola Visconti, Federica Parodi, B. Parodi, Lucia Casarino, Paolo DM Romano, Mariachiara Buccarelli, Roberto Pallini M. D, Quintino Giorgio D’Alessandris, A Montori, Emanuela Pilozzi et al. · 2020 · International Journal of Cancer
8. KRT17 as a prognostic biomarker for stage II colorectal cancer
   Daisuke Ujiie, Hirokazu Okayama, Katsuharu Saito, Mai Ashizawa, Aung Kyi Thar Min, Eisei Endo, Koji Kase, Leo Yamada, Tomohiro Kikuchi, Hiroyuki Hanayama et al. · 2019 · Carcinogenesis
9. Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis
   Changwen Jing, Rong Ma, Haixia Cao, Zhuo Wang, Siwen Liu, Dan Chen, Yang Feng Wu, Junying Zhang, Jianzhong Wu · 2019 · Cancer Medicine
10. Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma
    Harald Surowy, A.K. Giesen, J. Otte, Reinhard Büttner, D. Falkenstein, H. Friedl, Friedegund Elke Meier, Patrick Petzsch, Thorsten Wachtmeister, Dana Westphal et al. · 2018 · British Journal of Dermatology
11. Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology
    Vaidehi Jobanputra, Kazimierz O. Wrzeszczyński, Reinhard Büttner, Carlos Caldas, Edwin P. J. G. Cuppen, Sean Michael Grimmond, Torsten Haferlach, Charles Grenfell Mullighan, Anna Schuh, Olivier Elemento · 2021 · Seminars in Cancer Biology
12. Phosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities
    Barbora Šalovská, Erli Gao, Sophia Müller‐Dott, Wenxue Li, Carlos Chacon Cordon, Shisheng Wang, Aurélien J. F. Dugourd, George Rosenberger, Julio Sáez-Rodríguez, Yansheng Liu · 2023 · Clinical and Translational Medicine
13. Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer
    Alexandros Georgiou, Adam Stewart, David Cunningham, Udai Banerji, Steven R. Whittaker · 2020 · Molecular Cancer Research
14. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
    Fichtner, Michael, Bozkurt, Emir, Salvucci, Manuela, McCann, Christopher, McAllister, Katherine A., Halang, Luise, Düssmann, Heiko, Kinsella, Sinéad, Crawford, Nyree, Sessler, Tamas et al. · 2020 · Cell Death & Disease
15. A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy
    Paolo Luraghi, Viola Bigatto, Élia Cipriano, Gigliola Reato, Francesca Orzan, Francesco Paolo Sassi, Francesca De Bacco, Claudio Isella, Sara E. Bellomo, Enzo Médico et al. · 2017 · Clinical Cancer Research
16. FGFR2 amplification in colorectal adenocarcinoma
    Jamal H. Carter, Catherine E. Cottrell, Samantha N. McNulty, Katinka A. Vigh‐Conrad, Stephen Lamp, Jonathan W. Heusel, Eric James Duncavage · 2017 · Molecular Case Studies
17. Standardising RNA profiling based biomarker application in cancer—The need for robust control of technical variables
    Peter Stewart, Susan D. Richman, Tim Maughan, Mark Lawler, Philip D. Dunne, Manuel Salto‐Tellez · 2017 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
18. Serum- and Glucocorticoid-induced Kinase Sgk1 Directly Promotes the Differentiation of Colorectal Cancer Cells and Restrains Metastasis
    Lennard Y. W. Lee, Connor E. Woolley, Thomas Starkey, Sujata Biswas, Tia Mirshahi, Chiara Bardella, Stefania Segditsas, Shazia Irshad, Ian P.M. Tomlinson · 2018 · Clinical Cancer Research
19. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
    Yang, Mingli, Davis, Thomas B., Pflieger, Lance, Nebozhyn, Michael V., Loboda, Andrey, Wang, Heiman, Schell, Michael J., Thota, Ramya, Pledger, W. Jack, Yeatman, Timothy J. · 2022 · BMC Cancer
20. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration
    Bastin, Jean, Sroussi, Marine, Nemazanyy, Ivan, Laurent-Puig, Pierre, Mouillet-Richard, Sophie, Djouadi, Fatima · 2023 · Journal of Translational Medicine
21. Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT
    Angel C.Y. Yu, Yi‐Jye Chern, Peter G. Y. Zhang, Clarissa C. Pasiliao, Mahbuba Rahman, George J. Chang, Jianhua Ren, Isabella T. Tai · 2021 · Cancer Biology & Therapy
22. Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
    Sheng‐Yen Hsiao, Hong-Lin He, Teng-Song Weng, Cheng-Yao Lin, Chien‐Ming Chao, Wen‐Tsung Huang, Chao‐Jung Tsao · 2021 · Case Reports in Oncology
23. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer
    Gabriele Picco, Consalvo Petti, Francesco Paolo Sassi, Katia Grillone, Giorgia Migliardi, Teresa Rossi, Claudio Isella, Federica Di Nicolantonio, Ivana Sarotto, Anna Sapino et al. · 2016 · JNCI Journal of the National Cancer Institute
24. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR
    Andrea Sartore Bianchi, Salvatore Siena, Giuseppe Tonini, Alberto Bardelli, Daniele Santini · 2016 · Cancer Treatment Reviews
25. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
    Albert Bosch-Vilaró, Bart Jacobs, Valentina Pomella, Layka Abbasi Asbagh, Richard E. Kirkland, Joe Michel, Sharat Singh, Xinjun Liu, Phillip Kim, Gregory E. Weitsman et al. · 2016 · Oncotarget
26. New perspectives for targeting therapy in ALK-positive human cancers
    Simin Zhao, Jian Li, Qingxin Xia, Kangdong Liu, Zigang Dong · 2023 · Oncogene
27. Detection of Proteome Changes in Human Colon Cancer Induced by Cell Surface Binding of Growth-Inhibitory Human Galectin‑4 Using Quantitative SILAC-Based Proteomics
    Malwina Michalak, Uwe H. Warnken, Sabine André, Martina Schnölzer, Hans‐Joachim Gabius, Juergen Kopitz · 2016 · Journal of Proteome Research
28. Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA
    Andrea Z. Lai, Alexa Betzig Schrock, Rachel Erlich, Jeffrey S. Ross, Vincent A. Miller, Evgeny Yakirevich, Siraj Mahamed Ali, Fadi Braiteh · 2017 · The Oncologist
29. CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition
    Jasmin B. Post, Nizar Hami, Alexander E.E. Mertens, Suraya Elfrink, Johannes L. Bos, Hugo J.G. Snippert · 2019 · Oncotarget
30. Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors
    Alicja Pawlak, Ewa Zioło, Anna Fiedorowicz, Klaudyna Fidyt, Leon Strządała, Wojciech Kałas · 2016 · BMC Cancer
31. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
    Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda R. Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Liyamali Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer et al. · 2024 · British Journal of Cancer
32. APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
    Ramya Thota, Mingli Yang, Lance T. Pflieger, Michael J. Schell, Malini Rajan, Thomas B. Davis, Heiman Wang, Angela P. Presson, Warren Jack Pledger, Timothy Joseph Yeatman · 2021 · Cancers
33. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer
    Javier Ros, Iosune Baraibar, Giulia Martini, Francesc Salvà, Nadia Saoudi Gonzalez, José Luis Cuadra‐Urteaga, Rodrigo Dienstmann, Josep M. Tabernero, Elena Élez · 2021 · Current Treatment Options in Oncology
34. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
    Anxo Río-Vilariño, Aiora Cenigaonandia‐Campillo, Ana García-Bautista, Pedro A. Mateos‐Gómez, Marina I. Schlaepfer, Laura del Puerto‐Nevado, Oscar Aguilera, Laura García‐García, Carlos Galeano, Irene de Miguel et al. · 2024 · British Journal of Cancer
35. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK
    Tao Lu, Yanmei Zou, Guogang Xu, Jane A. Potter, Garry L. Taylor, Qiuhong Duan, Qin Yang, Huihua Xiong, Hong Qiu, Dawei Ye et al. · 2016 · Oncotarget
36. Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
    Ghazi, Alexandre, Le Corre, Delphine, Pilati, Camilla, Taieb, Julien, Aparicio, Thomas, Didelot, Audrey, Dedhar, Shoukat, Mulot, Claire, Le Malicot, Karine, Djouadi, Fatima et al. · 2021 · OncoImmunology
37. Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies
    Yan Li, Bing Wang, Fahan Ma, Dongxian Jiang, Ying Wang, Kai Li, Subei Tan, Jinwen Feng, Yunzhi Wang, Zhaoyu Qin et al. · 2023 · Cell Reports Medicine
38. Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges
    Qin Dang, Lulu Zuo, Xinru Hu, Zhaokai Zhou, Shuang Chen, Shutong Liu, Yuhao Ba, Anning Zuo, Hui Xu, Siyuan Weng et al. · 2024 · Cancer Medicine
39. TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
    Kyungsoo Jung, Joon‐Seok Choi, Beom-Mo Koo, Yu Jin Kim, Jiyoung Song, Minjung Sung, Eun Sol Chang, Ka‐Won Noh, Sungbin An, Mi‐Sook Lee et al. · 2020 · Cancer Research and Treatment
40. Patient‐derived xenograft model in colorectal cancer basic and translational research
    Xiaofeng Liu, Zechang Xin, Kun Wang · 2022 · Animal Models and Experimental Medicine
41. Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
    Mingli Yang, Michael J. Schell, Andrey P. Loboda, Michael Nebozhyn, Jiannong Li, Jamie K. Teer, Warren Jack Pledger, Timothy Joseph Yeatman · 2019 · Cancer Epidemiology Biomarkers & Prevention
42. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
    Sujin Kim, Nayoung Kim, Keunsoo Kang, Wonkyung Kim, Jonghwa Won, Jeonghee Cho · 2019 · Cells
43. The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer
    Martina Mazzeschi, Michela Sgarzi, Donatella Romaniello, Valerio Gelfo, Carola Cavallo, Francesca Ambrosi, Alessandra Morselli, Carmen Miano, Noemi Laprovitera, Cinzia Girone et al. · 2022 · Journal of Experimental & Clinical Cancer Research
44. XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients
    Simonetta Maria Leto, Elena Grassi, Marco Avolio, Valentina Vurchio, Francesca Cottino, Martina Ferri, Eugenia Rosalinda Zanella, Sofia Borgato, Giorgio Corti, Laura di Blasio et al. · 2024 · Nature Communications
45. Treatment Individualization in Colorectal Cancer
    Robin M.J.M. van Geel, Jos H. Beijnen, René Bernards, Jan H.M. Schellens · 2015 · Current Colorectal Cancer Reports
46. Stromal Galectin-1 Promotes Colorectal Cancer Cancer-Initiating Cell Features and Disease Dissemination Through SOX9 and β-Catenin: Development of Niche-Based Biomarkers
    Kai‐Yen Peng, Shih Sheng Jiang, Yu‐Wei Lee, Fang‐Yu Tsai, Chia‐Chi Chang, Li‐Tzong Chen, Betty Linju Yen · 2021 · Frontiers in Oncology
47. Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer
    Hamzeh Kayhanian, William C. H. Cross, Suzanne E. M. van der Horst, Panagiotis Barmpoutis, Eszter Lakatos, Giulio Caravagna, Luis Zapata, Arne van Hoeck, Sjors Middelkamp, Kevin Litchfield et al. · 2024 · Nature Genetics
48. Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
    Mariangela Russo, Simona Lamba, Annalisa Lorenzato, Alberto Sogari, Giorgio Corti, Giuseppe Rospo, Benedetta Mussolin, Monica Montone, Luca Lazzari, Sabrina Arena et al. · 2018 · Nature Communications
49. NFATC3–PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines
    Jee-Eun Jang, Hwang‐Phill Kim, Sae‐Won Han, Hoon Sik Jang, Si-Hyun Lee, Sang‐Hyun Song, Duhee Bang, Tae‐You Kim · 2018 · Cancer Research and Treatment
50. BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer
    Fabiana Conciatori, Chiara Bazzichetto, Carla Azzurra Amoreo, Isabella Sperduti, Sara Donzelli, Maria Grazia Diodoro, Simonetta Buglioni, Italia Falcone, Senji Shirasawa, Giovanni Blandino et al. · 2020 · Communications Biology
51. Characterization of novel low passage primary and metastatic colorectal cancer cell lines
    Arnoud Boot, Jaap van Eendenburg, Stijn Crobach, Dina Ruano, Frank M. Speetjens, Jan J. Calame, Jan Oosting, Hans M. Morreau, Tom van Wezel · 2016 · Oncotarget
52. Piperine Induces Apoptosis and Cell Cycle Arrest via Multiple Oxidative Stress Mechanisms and Regulation of PI3K/Akt and MAPK Signaling in Colorectal Cancer Cells
    Wan‐Ling Chang, Jyun-Yu Peng, Chain-Lang Hong, Pei-Ching Li, Soi Moi Chye, Fung‐Jou Lu, Huei-Yu Lin, Ching‐Hsein Chen · 2025 · Antioxidants
53. The RNA-Binding Protein ESRP1 Modulates the Expression of RAC1b in Colorectal Cancer Cells
    Marta Manco, Ugo Ala, Daniela Cantarella, Emanuela Tolosano, Enzo Médico, Fiorella Altruda, Sharmila Fagoonee · 2021 · Cancers
54. Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100
    Brian Park, Paromita Raha, Jim Pankovich, Mark Bazett · 2022 · Cancers
55. Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics
    Gabriel Cutshaw, Neeraj Joshi, Xiaona Wen, Elizabeth Quam, Galina Bogatcheva, Nora Ali Hassan, Saji Uthaman, Joshua R. Waite, Soumik Sarkar, Bhuminder Singh et al. · 2024 · Angewandte Chemie International Edition
56. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report
    Xi He, Xiao‐Dong Jiao, Ke Liu, Bao‐Dong Qin, Ying Wu, Yan Ling, Jun Liu, Aqiao Xu, Kun Song, Yuan‐Sheng Zang · 2021 · JCO Precision Oncology
57. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
    Sogari, Alberto, Rovera, Emanuele, Grasso, Gaia, Mariella, Elisa, Reilly, Nicole Megan, Lamba, Simona, Mauri, Gianluca, Durinikova, Erika, Vitiello, Pietro Paolo, Lorenzato, Annalisa et al. · 2024 · Cell Reports Medicine
58. Proteomics-Based Evidence for a Pro-Oncogenic Role of ESRP1 in Human Colorectal Cancer Cells
    Ugo Ala, Marta Manco, Giorgia Mandili, Emanuela Tolosano, Francesco Novelli, Paolo Provero, Fiorella Altruda, Sharmila Fagoonee · 2020 · International Journal of Molecular Sciences
59. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
    Deepak Vangala, Swetlana Ladigan, Sven Thorsten Liffers, Soha Noseir, Abdelouahid Maghnouj, Tina-Maria Götze, Berlinda Verdoodt, Susanne Klein‐Scory, Laura Godfrey, Martina K. Zowada et al. · 2021 · Genome Medicine
60. Basal level of autophagy and MAP 1 LC 3B‐ II as potential biomarkers for DHA ‐induced cytotoxicity in colorectal cancer cells
    Helle Samdal, Malin Alise Sandmoe, Lene Christin Olsen, Elaf Ali Hadi Jarallah, Therese S. Høiem, Svanhild Arentz Schønberg, Caroline Hild Hakvåg Pettersen · 2018 · FEBS Journal
61. NUDT7 Loss Promotes KrasG12D CRC Development
    Jinsoo Song, Sujeong Park, Jinjoo Oh, Deokha Kim, Ji Hyun Ryu, Won Cheol Park, In‐Jeoung Baek, Xi Cheng, Xin Lü, Eun‐Jung Jin · 2020 · Cancers
62. In vitro Biological Tests as the First Tools To Validate Magnetic Nanotheranostics for Colorectal Cancer Models
    María Julia Martín, Claudia Gentili, Verónica Lassalle · 2020 · ChemMedChem
63. Using Two Peptide Isotopologues as Internal Standards for the Streamlined Quantification of Low-Abundance Proteins by Immuno-MRM and Immuno-MALDI
    Sahar Ibrahim, Bjoern C. Froehlich, Adriana Aguilar‐Mahecha, Raquel S. Aloyz, Oliver Poetz, Mark Basik, Gerald Batist, René Peiman Zahedi, Christoph H. Borchers · 2020 · Analytical Chemistry
64. Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors
    Kyrillus Samaan Shohdy, Rohan Bareja, Michael Sigouros, David C. Wilkes, Princesca Dorsaint, Jyothi Manohar, Daniel Bockelman, Jenny Xiang, Rob Kim, Kentaro Ohara et al. · 2021 · npj Genomic Medicine
65. 2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology
    Richard J. Epstein, Tian Li, Yan Fei Gu · 2021 · Journal of Oncology
66. EGFR-Targeted Antibody–Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells
    Leila Pisheh, Serena Matis, Martina Taglieri, Linda Di Gregorio, Roberto Benelli, Alessandro Delli Poggi · 2024 · Cancers
67. Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon Cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes
    Nhi Thi Hong Nguyen, Souad R. Sennoune, Gunadharini Dharmalingam-Nandagopal, Sathish Sivaprakasam, Yangzom Doma Bhutia, Vadivel Ganapathy · 2024 · Cells
68. The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
    Stephanie Matschos, Florian Bürtin, Said Kdimati, Mandy Radefeldt, Susann Krake, Friedrich Prall, Nadja Engel, Mathias Krohn, Bianca Micheel, Michael Kreutzer et al. · 2021 · Cancers
69. Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines
    Michael C. Gock, Christina Susanne Mullins, Carina Bergner, Friedrich Prall, Robert Ramer, Anja Göder, Oliver Holger Krämer, Falko Lange, Bernd Joachim Krause, Ernst Klar et al. · 2018 · World Journal of Gastroenterology
70. Multi‐omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155
    Tianzuo Zhan, Verena Faehling, Benedikt Rauscher, Johannes Betge, Matthias P. Ebert, Michael Boutros · 2020 · International Journal of Cancer
71. Mutational signatures of colorectal cancers according to distinct computational workflows
    Paolo Battuello, Giorgio Corti, Alice Bartolini, Annalisa Lorenzato, Alberto Sogari, Mariangela Russo, Federica Di Nicolantonio, Alberto Bardelli, Giovanni Crisafulli · 2024 · Briefings in Bioinformatics
72. Ruthenium Drug BOLD-100 Regulates BRAF MT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation
    Daryl Griffin, Robbie Carson, Debbie Moss, Tamas Sessler, Deborah P. Lavin, Vijay Kumar Tiwari, Shivaali Karelia, Richard D. Kennedy, Kienan I. Savage, Simon S. McDade et al. · 2024 · Molecular Cancer Research
73. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development
    Vadim Bernard‐Gauthier, Anne Mahringer, Matthew Vesnaver, Gert Fricker, Ralf Schirrmacher · 2017 · Bioorganic & Medicinal Chemistry Letters
74. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma
    Kshama Gupta, Jeremy Clifton Jones, Virgínea Farias, Yuri Mackeyev, Pankaj K. Singh, Alfredo Quiñones‐Hinojosa, Sunil Krishnan · 2022 · Frontiers in Oncology
75. Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line
    Michael C. Gock, Christina Susanne Mullins, Christine Harnack, Friedrich Prall, Robert Ramer, Anja Göder, Oliver Holger Krämer, Ernst Klar, Michael Linnebacher · 2018 · World Journal of Gastroenterology
76. Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis
    Lydia Brandl, Yina Zhang, Nina Kirstein, Andrea Sendelhofert, Sophie Luise Boos, Peter Jung, Florian R. Greten, Roland Rad, Antje Menssen · 2019 · Neoplasia
77. Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways
    Federica Invrea, Simona Punzi, Consalvo Petti, Rosalba Minelli, Michael D. Peoples, Christopher Aaron Bristow, Valentina Vurchio, Alessia Corrado, Alberto Bragoni, Caterina Marchiò et al. · 2021 · Cancers
78. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in <i>KRASG12C</i> -mutant Colorectal Cancer
    Khawaja, Hajrah, Briggs, Rebecca, Latimer, Cheryl H., Rassel, Mustasin, Griffin, Daryl, Hanson, Lyndsey, Bardelli, Alberto, Di Nicolantonio, Frederica, McDade, Simon S., Scott, Christopher J. et al. · 2023 · Molecular Cancer Therapeutics
79. Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer
    Erica Torchiaro, Marco Cortese, Consalvo Petti, Marco Basiricò, Federica Invrea, Alice D'Andrea, Letizia Franco, Dario Sangiolo, Enzo Médico · 2024 · Journal of Translational Medicine
80. Drug repositioning beyond the low-hanging fruits
    Miquel Duran‐Frigola, Lídia Mateo, Patrick Aloy · 2017 · Current Opinion in Systems Biology
81. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer
    Saikat Chowdhury, Ria Gupta, Joshua Millstein, Kangyu Lin, Valsala Haridas, Mohammad A. A. Zeineddine, Christine Megerdichian Parseghian, Heinz‐Josef Lenz, Scott Kopetz, John Paul Shen · 2023 · JCO Precision Oncology
82. Modeling Normal and Disordered Human Hematopoiesis
    Philip A. Beer, Connie J. Eaves · 2015 · Trends in cancer
83. How the Lab is Changing Our View of Colorectal Cancer
    Chiara Cremolini, Filippo Pietrantonio · 2016 · Tumori Journal
84. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
    Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S. Kim, Ying Wang, Patrick G. Gavin, Peter C. Lucas, Ashok Srinivasan, Carmen Joseph Allegra et al. · 2018 · PLoS ONE
85. Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development
    Anthony W.H. Chan, Yi Pan, JOANNA H.M. TONG, Raymond Wai Ming Lung, Johnny S‐H Kwan, Chit Chow, Edith K.Y. Tin, Lau‐Ying Chung, Hui Li, Shela Shu-Yan Wong et al. · 2020 · The Journal of Pathology
86. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update
    Iosune Baraibar, Javier Ros, Núria Mulet-Margalef, Francesc Salvà, Guillem Argilés, Giulia Martini, José Luis Cuadra‐Urteaga, Emilia Sardo, Davide Ciardiello, Josep M. Tabernero et al. · 2020 · Expert Review of Molecular Diagnostics
87. Development of Preclinical Models to Understand and Treat Colorectal Cancer
    Judith S. Sebolt · 2018 · Clinics in Colon and Rectal Surgery
88. High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer
    Steven P. Williams, Andrew S. Barthorpe, Howard W. Lightfoot, Mathew J. Garnett, Ultan McDermott · 2017 · Scientific Data
89. KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF‑β mediated epithelial‑mesenchymal transition
    Yaoyu Guo, Chuling Hu, Kuntai Cai, Guojie Long, Du Cai, Zhaoliang Yu, Xinxin Huang, Zerong Cai, Peishan Hu, Yufeng Chen et al. · 2024 · Molecular Medicine Reports
90. Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
    Elena Richiardone, Maria Virginia Giolito, Rim Al Roumi, Jérôme Ambroise, Romain Boidot, Bernhard Drotleff, Bart Ghesquière, Barbara Lupo, Livio Trusolino, Alberto Bardelli et al. · 2025 · Cancer Letters
91. Autocrine TGF-β/ZEB/microRNA-200 signal transduction drives epithelial-mesenchymal transition: Kinetic models predict minimal drug dose to inhibit metastasis
    Katja Rateitschak, Lars Kaderali, Olaf Wolkenhauer A, Robert Jaster · 2016 · Cellular Signalling
92. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth
    Hiroko Ishii, Maram Hussein Zahra, Atushi Takayanagi, Masaharu Seno · 2021 · International Journal of Molecular Sciences
93. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer
    Ahmad Zulkifli, Fiona H. Tan, Zammam Areeb, Sarah F. Stuart, Juliana Gomez, Lucia Paradiso, Rodney Brian Luwor · 2021 · International Journal of Molecular Sciences
94. Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
    Alessandro Parisi, Giampiero Porzio, Katia Cannita, Olga Venditti, Antonio Avallone, Roberto Filippi, Lisa Salvatore, Giampaolo Tortora, Marta Ribelli, Olga Nigro et al. · 2021 · Clinical Colorectal Cancer
95. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy forKRASmutant colorectal cancers
    Maria Sofia Fernandes, Soraia Melo, Sérgia Velho, Patrı́cia Carneiro, Fátima Carneiro, Raquel Seruca · 2016 · Oncotarget
96. Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review
    Tingting Hu, Jinbo Zhan, Li Li, Yan He, Yun Lin, Jingru Wang, Haiming Yu, Jianping Xiong, Ziling Fang, Jun Deng et al. · 2024 · The Oncologist
97. Promoting Biological Similarity by Collagen Microfibers in 3D Colorectal Cancer-Stromal Tissue: Replicating Mechanical Properties and Cancer Stem Cell Markers.
    Naoko Sasaki, Yoshiya Asano, Yukiko Sorayama, Chihiro Kamimura, S. Kitano, Shinji Irie, Ryohei Katayama, Hiroshi Shimoda, M. Matsusaki · 2024 · Acta Biomaterialia
98. DNA demethylation triggers cell free DNA release in colorectal cancer cells
    Valeria Pessei, Marco Macagno, Elisa Mariella, Noemi Congiusta, Vittorio Battaglieri, Paolo Battuello, Marco Viviani, Giulia Gionfriddo, Simona Lamba, Annalisa Lorenzato et al. · 2024 · Genome Medicine
99. Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer
    Adam Lafferty, Alice C. O’Farrell, Giorgia Migliardi, Niraj Khemka, Andreas Ulrich Lindner, Francesco Paolo Sassi, Eugenia Rosalinda Zanella, Manuela Salvucci, Evy Vanderheyden, Elodie Modave et al. · 2021 · Clinical Cancer Research
100. A prognostic six‐gene expression risk‐score derived from proteomic profiling of the metastatic colorectal cancer secretome
     Javier Robles, Laura Pintado‐Berninches, Issam Boukich, Beatriz Escudero, Vivian de los Rı́os, Rubén A. Bartolomé, Marta Jaén, Ángela Martín‐Regalado, María Jesús Fernández‐Aceñero, Juan Ignacio Imbaud et al. · 2022 · The Journal of Pathology Clinical Research